[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-cardiac-arrest-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-cardiac-arrest-syndrome":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,78,108,138,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100428455","the-holistic-health-care-of-post-cardiac-arrest-survivors-from-patients-health-to-family-resilience-100428455",false,"NCT04859270","The Holistic Health Care of Post-Cardiac Arrest Survivors: From Patient's Health to Family Resilience","Inclusion Criteria:\n\n1\\. Patients with non-traumatic cardiac arrest, who have successfully sustained return of spontaneous circulation for more than five minutes after resuscitation efforts.\n\nExclusion Criteria:\n\n1. Under 20 years of age\n2. Pregnant\n3. Terminally ill cancer patients or cancer patients who are unwilling to receive treatment\n4. When the ICU is over capacity and unable to provide intensive care.\n5. The patient or family members refused to participate in this study.","ALL","20 Years",{"count":18,"type":19},600,"ESTIMATED","OBSERVATIONAL","Post-cardiac arrest mortality remains high and proper care after cardiopulmonary resuscitation is an important clinical challenge. This prospective observational cohort aims to (1) identify the factors that affect short-term and long-term survival in post-cardiac arrest survivors and (2) investigate the patients and their families' health-related quality of life and psychological well-being.",[23],"Post-Cardiac Arrest Syndrome",[25,26,27],"Post-cardiac arrest","Holistic care","Family resilience","RECRUITING","2025-07-16",{"date":31,"type":32},"2025-07-18","ACTUAL",{"date":34,"type":32},"2021-04-12",{"date":36,"type":19},"2026-03-31",{"name":38,"class":39},"National Taiwan University Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100575766","hypothermia-versus-normothermia-after-extracorporeal-cardiopulmonary-resuscitation-for-out-of-hospital-cardiac-arrest-100575766","NCT06776549","Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest","Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest: A Cluster Randomized Trial (SAVE-J NEUROTHERM Trial)","J-NEURO","Inclusion Criteria:\n\n* OHCA\n* Age of 18-75 years, known or estimated\n* An initial cardiac arrest rhythm of ventricular fibrillation\u002Fpulseless ventricular tachycardia or pulseless electrical activity\n\nExclusion Criteria:\n\n* ECMO initiated after sustained return of spontaneous circulation (ROSC) and patients with sustained ROSC before ECMO initiation\n* OHCA of presumed non-cardiac etiology\n* Time from emergency call or witnessed arrest to hospital arrival of \\>60 min\n* Time from hospital arrival to ECMO initiation of \\>60 min\n* Pre-hospital ECPR\n* Unavailability of the ECMO heat exchanger for temperature control\n* Glasgow Coma Scale score before temperature control of \\>8\n* Core body temperature upon hospital arrival of ≤32ºC\n* Surgical intervention before temperature control (e.g., surgical intervention for the primary disease or complications related to resuscitation\u002FECMO procedures)\n* Do Not Attempt Resuscitation) order confirmed prior to temperature control\n* Limitations in intensive care before temperature control\n* Known cerebral performance category (CPC) of 3-4 before cardiac arrest\n* Known chronic obstructive pulmonary disease with home oxygen therapy\n* Known or suspected pregnancy\n* Concomitant illness, such as malignancy, shortens life expectancy (180-day survival unlikely)\n* Consent not obtained or withdrawn by the participant or surrogate\n* Other reasons, physician's decision not to enroll the patient","18 Years","75 Years",{"count":52,"type":19},468,"INTERVENTIONAL",[55],"NA","The SAVE-J NEUROTHERM trial is a cluster randomized trial that evaluated and compared the mortality risk, neurological outcomes, and adverse events between patients who underwent hypothermia and those who underwent normothermia after extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest.",[58,59,60,61],"Out-of-hospital Cardiac Arrest (OHCA)","ECMO Treatment","Temperature","Post Cardiac Arrest Syndrome",[63,64,65,66,67],"Cardiac arrest","Out-of-hospital cardiac arrest (OHCA)","Extracorporeal cardiopulmonary resuscitation (ECPR)","Temperature control","Post cardiac arrest syndrome (PCAS)","2025-06-26",{"date":70,"type":32},"2025-06-27",{"date":72,"type":32},"2025-01-06",{"date":74,"type":19},"2028-12-31",{"name":76,"class":39},"Kagawa University",28,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":53,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100299295","phase-3-xenon-for-neuroprotection-during-post-cardiac-arrest-syndrome-in-comatose-survivors-of-an-out-of-hospital-cardiac-arrest-100299295","NCT03176186","Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest","XePOHCAS - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome","XePOHCAS","Inclusion Criteria:\n\n1. Age at least 18 years but less than or equal to 80 years\n2. Presumed cardiac cause of arrest\n3. Sustained (\\>20 minutes) spontaneous circulation upon arrival in the emergency department\n4. No response to verbal commands on arrival to emergency department and prior to randomization (Glasgow Coma Scale score of \\\u003C8)\n5. Attending decision that patient is eligible for TTM\n\nExclusion Criteria:\n\n1. Written do not attempt resuscitation reported to providers before randomization\n2. Traumatic etiology of arrest, defined as concomitant blunt, penetrating, or burn-related injury, or uncontrolled bleeding or exsanguination\n3. Suspected or known stroke or intracranial hemorrhage\n4. Unwitnessed cardiac arrest\n5. No-flow (cardiac arrest to initiation of cardiopulmonary resuscitation\u002Fdefibrillation) time of \\>10 minutes\n6. Sustained restoration of spontaneous circulation (ROSC) greater than 30- minutes post-arrest\n7. Interval from arrival at the emergency department to randomization for intervention of \\>4 hours.\n8. Hypothermia (\\\u003C30°C core temperature)\n9. Bed-bound prior to cardiac arrest\n10. Unconsciousness before cardiac arrest (cerebral trauma, spontaneous cerebral hemorrhage, intoxication etc.)\n11. Coagulopathy\n12. Systolic arterial pressure \\\u003C80 mmHg or mean arterial pressure \\\u003C60 mmHg lasting more than 30 minutes after ROSC\n13. Known pregnancy\n14. Have received an investigational drug, device, or biologic product within 30-days\n15. Known terminal phase of chronic illness\n16. Hypoxemia (SaO2 \\\u003C85%) for \\>15 minutes after ROSC\n17. Inability to maintain SaO2 \\>90% on an FiO2 of 50%\n18. Having any other clinically significant laboratory abnormality, medical condition (such as intrinsic liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial\n19. Logistically impossible to provide intervention\n20. Have any condition that would impact the evaluation of modified Rankin Scale (mRS)","80 Years",{"count":88,"type":19},1436,[90],"PHASE3","XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management \\[TTM\\]) to xenon by inhalation plus standard-of-care post-cardiac arrest intensive care (including TTM).",[23],[94,95],"ischemic-reperfusion injury","out of hospital cardiac arrest","NOT_YET_RECRUITING","2025-04-02",{"date":99,"type":32},"2025-04-03",{"date":101,"type":19},"2026-03",{"date":103,"type":19},"2030-05",{"name":105,"class":106},"Invero Pharma, Inc.","INDUSTRY",10,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":53,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":136,"locationsCount":40},"100577478","lung-conservative-liquid-ventilation-for-the-induction-of-ultra-rapid-cooling-after-cardiac-arrest-100577478","NCT06798818","Lung-cOnservative Liquid VEntilation for the Induction of Ultra-Rapid COOLing After Cardiac Arrest","OverCool","Inclusion Criteria:\n\n* Patient resuscitated after extra- or intra-hospital cardiac arrest, from presumed cardiac or asphyxial origin, regardless of the heart rate initially recorded.\n* Age between 18 and 84 years old\n* Time between collapse and return of spontaneous circulation (ROSC) \\\u003C 60 min\n* Presumption, at the time of inclusion, of a possibility of starting Vent2Cool within a period of less than 120 min after ROSC.\n* Unconscious (GCS \\\u003C8, not able to obey verbal commands after sustained ROSC)\n* Patient affiliated with a social security system (If applicable)\n* Consent of the member of patients' family or that of the trusted person if present and able to understand; otherwise certificate of emergency inclusion in compliance with applicable regulations.\n* Vent2Cool must be connected to a standard cuffed ETT of 7.0 mm to 9.0 mm internal diameter for the procedure.\n\nExclusion Criteria:\n\n* Conscious patient\n* Patient Ideal Body Weight less than 40 kgs or more than 93 kgs\n* Traumatic cardiac arrest, drowning, exsanguination, or sepsis\n* Temperature at admission \\\u003C 34.0°C\n* Need for veno-arterial extracorporeal circulation (Extracorporeal membrane of oxygenation, ECMO) before return of spontaneous circulation (refractory cardiac arrest)\n* One of the following signs at echocardiography at hospital admission:\n\n  * Acute cor pulmonale, defined by right ventricular enlargement with interventricular septal deviation, associated with a Tricuspid Annular Plane Systolic Excursion (TAPSE) \\\u003C 12 mm and need for vasopressor agents\n  * Time-velocity integral of subaortic flow \\\u003C 10 m\u002Fs\n* Wrong positioning or damage of the endotracheal tube.\n* Women under 50 years old (childbearing age) or for women of \\>50 years old, a positive pregnancy test (urinary) in case of pregnancy suspicion by the investigator. Possible breastfeeding during the study.\n* Suspicion of intracranial bleeding\n* History of severe Chronic Obstructive Pulmonary Disease (COPD) with long-term home oxygen therapy\n* Acute respiratory pathology (pneumothorax, pleurisy, pneumonia, suspicion of contusion or intra-pulmonary hemorrhage following resuscitation)\n* COVID-19 positive test in case of clinical suspicion and\u002For epidemic context\n* Excessive mucus in the upper airways\n* Patient presenting at least one of the following criteria in the mechanical ventilation parameters at inclusion:\n\n  * PEEP \\> 8 cm H2O\n  * Plateau pressure\\> 25 cmH2O\n  * Driving pressure\\> 15cmH2O\n* Patient with at least one of the following criteria at inclusion:\n\n  * PaO2\\\u003C 80 mmHg\n  * PaO2 \u002F FiO2\\\u003C 150 mmHg\n  * PaCO2\\> 48 mmHg","84 Years",{"count":117,"type":19},24,[55],"Out-of-hospital cardiac arrest (OHCA) affects over 356,000 individuals annually in the United States, with fewer than 10% surviving to hospital discharge, mirroring statistics from Europe. Post-cardiac arrest syndrome (PCAS), a condition causing multi-organ dysfunction, is a leading cause of mortality despite successful resuscitation efforts. Targeted temperature management (TTM) is recommended for comatose patients post-resuscitation to mitigate PCAS, but optimal temperature targets and cooling methods remain unclear. Experimental studies suggest that therapeutic hypothermia (32-34°C), induced rapidly after resuscitation, may provide significant clinical benefits.\n\nTotal liquid ventilation (TLV) with breathable liquids has been proposed to achieve ultra-rapid therapeutic hypothermia (URTH). This approach uses the lungs as a heat exchanger to achieve ultra-rapid cooling while maintaining normal gas exchange. It enables a reduction in core body temperature to the hypothermic range (33.0 ± 0.5°C) within 45 minutes in relevant experimental models.\n\nThe OverCool study is an open-label, single-arm, multi-centric pilot trial designed to evaluate the performance and safety of Vent2Cool, a medical device intended to induce ultra-rapid therapeutic hypothermia by TLV in resuscitated cardiac arrest patients. The primary objective is to demonstrate Vent2Cool's ability to achieve a target core temperature of 33.0 ± 0.5°C within 60 minutes from start of procedure in resuscitated patients admitted to the Intensive Care Unit following intra- or extra-hospital cardiac arrest. Secondary objectives include assessing procedural safety, cooling performance, feasibility in emergency settings, clinical outcomes, and the impact on biological markers.",[121,61],"Cardiac Arrest",[123,124,125,126,127,128,129],"Cooling","Targeted Temperature Management","ROSC","Resuscitated Cardiac Arrest","Out of Hospital cardiac arrest","Therapeutic Hypothermia","liquid ventilation","2025-01-28",{"date":132,"type":32},"2025-01-29",{"date":134,"type":19},"2025-03",{"date":101,"type":19},{"name":137,"class":106},"ORIXHA",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":53,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100508087","phase-3-the-danish-out-of-hospital-cardiac-arrest-study-100508087","NCT05895838","The Danish Out-of-Hospital Cardiac Arrest Study","The Danish Out-of-Hospital Cardiac Arrest Study - a Randomized, Placebo-controlled, Double-blind, Multi Center Trial","DANOHCA","Inclusion Criteria:\n\n1. Age ≥18 years\n2. OHCA of presumed cardiac cause\n3. Sustained ROSC, defined as persistent signs of circulation and no need for chest compressions or mechanical circulatory support for 20 minutes\n4. Unconsciousness (GCS \\\u003C9) (patients not able to obey verbal commands) after sustained ROSC at the time of randomization\n\nExclusion Criteria:\n\n1. Females of childbearing potential if pregnancy is suspected (unless a negative HCG test can rule out pregnancy within the inclusion window)\n2. Known bleeding diathesis (medically induced coagulopathy (e.g. warfarin, NOAC, clopidogrel) does not exclude the patient)\n3. Suspected or confirmed acute intracranial bleeding\n4. Suspected or confirmed acute stroke\n5. Unwitnessed asystole\n6. Known limitations in therapy and Do Not Resuscitate-order\n7. Known disease making 180 days survival unlikely\n8. Known pre-arrest CPC 3 or 4 functional status\n9. \\>3 hours (180 minutes) from ROSC to screening\n10. Systolic blood pressure \\\u003C80 mm Hg despite fluid loading\u002Fvasopressor and\u002For inotropic medication (If the systolic blood pressure is recovering during the inclusion window of 180 minutes the patient may be included)\n11. Use of intra-aortic balloon pump\u002Faxial flow device\u002FECMO (If the patient is weaned and the device is removed during the inclusion window of 180 minutes the patient may be included)\n12. Temperature on admission \\\u003C30°C\n13. Known allergy for dexamethasone or olanzapine\n14. Ongoing (within 48 h) treatment with olanzapine or dexamethasone\n15. Known back or hip condition that precluded the patients from being positioned with backrest from 0 to 45-degree angle\n16. Known or suspected Long QT Syndrome (LQTS)\n17. Known active fungal disease. Localized skin lesions do not exclude patients from inclusion\n18. Estimated body weight \\\u003C45kg",{"count":147,"type":19},1000,[90],"After resuscitation from Out-of-Hospital Cardiac Arrest (OHCA) patients experience Post Cardiac Arrest Syndrome due to ischemia and reperfusion injury. It consists of systemic inflammation, cerebral and myocardial dysfunction, and the condition that led to the arrest. Most OHCA patients will receive critical care intubated in an Intensive Care Unit (ICU). Despite this \\~50% die; mainly due to brain injury. Several targets can be considered for improving outcomes. To dampen systemic inflammation and optimize cerebral perfusion seem important. Deep sedation has been required for targeted temperature management (TTM) but may also be brain protective. After end of sedation, many patients have some cerebral dysfunction that may facilitate delirium.\n\nThe aim of this trial is therefore to improve treatment of comatose OHCA patients by evaluating 4 interventions in a factorial design addressing each of these targets in a randomized clinical trial:\n\n1. Systemic inflammation: Anti-inflammatory treatment with high dose steroids (dexamethasone) or placebo.\n2. Cerebral perfusion: Backrest elevation during sedation at 5 or 35 degrees.\n3. Duration of sedation: Early wakeup call and potential extubation at ≤6 hours after admission or later as current standard practice at 28-36 hours.\n4. Delirium: Prophylactic treatment with anti-psychotic medication (olanzapine) or placebo.\n\nThe trial is designed as a phase III trial, randomizing 1000 patients at Danish cardiac arrest centers.\n\nThe primary endpoint is 90 days all-cause mortality for the interventions targeting systemic inflammation and cerebral perfusion, while it is days alive outside of hospital within 30 days for the interventions concerning duration of sedation and delirium.\n\nThe trial has potential to improve outcomes for comatose OHCA patients - a group with a grave prognosis with currently only limited evidence-based treatments.",[151,23],"Out-Of-Hospital Cardiac Arrest",[151,23,153,154,155,156,157],"Systemic Inflammatory Response Syndrome","Inflammation","Cerebral perfusion","Sedation","Delirium","2025-01-21",{"date":160,"type":32},"2025-01-24",{"date":162,"type":32},"2023-06-16",{"date":164,"type":19},"2027-12",{"name":166,"class":39},"Christian Hassager",5,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":86,"enrollmentInfo":176,"targetDuration":16,"studyType":20,"phases":4,"briefSummary":178,"conditions":179,"keywords":184,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":40},"100387892","post-surgery-extracorporeal-life-support-100387892","NCT04330651","Post-Surgery Extracorporeal Life Support","Outcomes' Predictors in Post-Surgery Extracorporeal Life Support","PC-ECLS","Inclusion Criteria:\n\n* Patients underwent cardiac surgery\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years",{"count":177,"type":19},500,"Extracorporeal Life Support (ECLS) may provide pulmonary and circulatory support for patients with acute heart failure refractory to conventional medical therapy. However, indications and effectiveness of ECLS engagement post-surgery remains a concern. The investigators sought to analyze indications, modality and outcomes of PS-ECLS, to identify predictors of early and midterm survival after PS-ECLS. The investigators have recorded prospectively, and analysed data of 209 consecutive PS-ECLS patients between January 2004 and December 2018. Demographic and clinical data before, during and after PS-ECLS were collected and their influence on hospital mortality and outcomes (early and midterm) will analyse. Multivariate analysis of pre PS-ECLS implantation factors (as age, female sex , insulin-dependent diabetes, pulmonary hypertension, STS, type of surgical procedure data, pre-ECLS blood lactate level) will be made for identify prognostic risk factors of in-hospital mortality. Overall survival will be analysed, at 6 months,1-year and 5-years, respectively and the factors influencing mild\u002Fterm outcome will be investigated.",[180,181,182,61,183],"Cardiogenic Shock","Extracorporeal Life Support","Extracorporeal Membrane Oxygenation Complication","Post-cardiac Surgery",[185,186,187,188,189,190],"extracorporeal life support","ecls","ecmo","outocome","prognostic factors","extracorporeal membrane oxygenation","2021-04-27",{"date":193,"type":32},"2021-04-28",{"date":195,"type":4},"2004-01",{"date":197,"type":19},"2029-01-31",{"name":199,"class":39},"University of Florence"]